Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development

Business Wire November 8, 2018

Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018

Business Wire October 25, 2018

New Research: Key Drivers of Growth for Haverty Furniture Companies, BLACKLINE INC, MagnaChip Semiconductor, Kinross Gold, Aurinia Pharmaceuticals, and NEXEO SOLUTIONS — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire October 16, 2018

Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis

Business Wire September 25, 2018

Aurinia to Participate in Upcoming Investor Conferences

Business Wire September 19, 2018

Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018

Business Wire August 28, 2018

Aurinia Reports Second Quarter Financial Results and Operational Highlights

Business Wire August 9, 2018

Aurinia Pharmaceuticals to Release Second Quarter 2018 Financial Results on August 9, 2018

Business Wire July 30, 2018

Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

Business Wire July 11, 2018

Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin

Business Wire June 25, 2018

Aurinia Announces Results of Annual General Meeting

Business Wire June 22, 2018

Factors of Influence in 2018, Key Indicators and Opportunity within Shinhan Financial Group, Aurinia Pharmaceuticals, Delphi Technologies, Green Plains Partners LP, Sprague Resources LP, and CRH — New Research Emphasizes Economic Growth

GlobeNewswire June 1, 2018

Aurinia Reports First Quarter Financial Results and Operational Highlights

Business Wire May 10, 2018

Aurinia Pharmaceuticals Recognizes World Lupus DayTM with Activities Focused on Raising Awareness of Lupus Nephritis

Business Wire May 10, 2018

Aurinia Pharmaceuticals to Release First Quarter 2018 Financial Results on May 10, 2018

Business Wire May 1, 2018

Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018

Business Wire April 25, 2018

New Research Coverage Highlights SINOPEC Shangai Petrochemical, Aurinia Pharmaceuticals, Valeant Pharmaceuticals International, NTT DOCOMO, Southern Missouri, and KNOT Offshore Partners LP — Consolidated Revenues, Company Growth, and Expectations for 2018

GlobeNewswire April 9, 2018

Aurinia Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018

Business Wire April 2, 2018

Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights

Business Wire March 15, 2018

Aurinia Pharmaceuticals Inc. to Host Earnings Call

Accesswire March 15, 2018